Tor Härnqvist, MD, discusses immune testing after invasive pneumococcal disease, serotype-informed vaccine selection, and pharmacists' role in supporting patients on immunoglobulin therapy.
|Articles|September 24, 2015
Bristol-Myers Squibb to Take Part in Leerink Partners Inaugural Immuno-Oncology Roundtable Conference
Bristol-Myers Squibb will take part in Leerink Partners Immuno-Oncology Roundtable on October 1.
Advertisement
PRESS RELEASE
NEW YORK--(
Investors and the general public are invited to listen to a live webcast of the session at
Advertisement
Related to this article
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
In the phase 2 ZUPREME 1 trial, the once-weekly amylin analog was well tolerated, with nausea mostly mild and limited to dose escalation.
Post hoc STEP UP data at EASD 2026 show liver fat fell from 8.8% to 3.1% at 72 weeks in a 55-person MRI subgroup, though no placebo comparison was reported.
Despite the controversy surrounding mRNA's role in the COVID-19 response, the technology's broader promise—to prevent, treat, and even cure a host of diseases—is coming into focus.
Age is the leading factor in influenza vaccine selection, and vaccination remains effective well beyond the ideal September-to-October window.
As Pharmacy Technician Day approaches, the CEO of the Pharmacy Technician Certification Board argues that real recognition means career ladders, consistent scope regulations, and investment in certification.
Advertisement
Advertisement